Full Press Release Details
Turn Therapeutics' GX-03 Technology Named
as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine
Turn's Topical IL36/IL31 Inhibitor Named
Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics
Los Angeles, CA - November 11, 2025 - Turn
Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious
disease therapies, today announced it has been named as one of the "Five
Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine.
"We are honored to have our GX-03 technology
be recognized as a top innovation by this widely read online magazine and this surprise designation further validates our goal of bringing
best-in-class eczema products to patients in need," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics.
"IL-36 is implicated in the inflammatory cascade behind atopic dermatitis, eczema and psoriasis, and our technology, with its novel
mechanism of action, represents the first topical agent to address this target, offering patients a potential alternative to systematics
and injectables. Our studies have demonstrated GX-03's ability to inhibit several key targets including IL-36 alpha, IL-31, as
well as IL-4 and IL-36 gamma, all of which are linked to both eczema and psoriasis. We are working diligently to bring our proprietary
pipeline of therapeutics to market and look forward to announcing topline data from our lead program in severe eczema in early 2026."
Patient Care Online is a comprehensive educational and clinical
news resource for office-based care clinicians of all backgrounds. Using a variety of media, Patient Care Online provides practical
information across the range of disease states and conditions seen daily in frontline clinical practice. Clinicians come to Patient
Care Online for news on drug approvals and commentary on the most current research, for video and podcast interviews with primary
investigators and clinician thought leaders, for slide shows that provide at-a-glance highlights of clinical trials, professional society
guidelines, and trending data, all developed with a focus on application to improve patient care.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing
products for dermatology, wound care, and infectious disease. The Company has received three FDA clearances for its proprietary wound
and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing
global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to
public health innovation.
Forward-Looking Statement
Certain statements in this press release
may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking
statements contained in this press release may be identified by the use of words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project," "suggest,"
"target," "aim," "should," "will," "would," or the negative of these words
or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on
Turn's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including
risks related to the timing and effectiveness of the Company's registration statement, the success of development programs, and
the Company's ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results
to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in
general, see the risk disclosures in the Company's filings with the SEC. All such forward-looking statements speak only as of the
date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future
events, or otherwise.
Monique Kosse, Managing Director